The relationship of cathepsin-k level with some biochemical and hematogical variables in women with osteoporosis, pregnant and menopausal

Abstract

In this study, the biochemical and hematological variables in 180 patients (women) between 17 and 75 years old were hospitalized at Al-Sadr Teaching Hospital in Najaf Iraq between April and July 2023. The patients were devised in 4 different group studies with 180 patients in each group consisting of 45 women: female with osteoporosis in the range age 22-35, a pregnant female in range age 17-37, female menopause range age 45-75, and healthy females in range age 19-65 as the control group. The biochemical variables such as level of Cathepsin K (Cath-k) concentration, Estradiol (E2) concentration, vitamin D (Vit -D), and parathyroid hormone (PTH) concentration in women with osteoporosis, menopause, pregnant and healthy women were evaluated. In addition, the hematological variables: red blood cells (RBCs), hemoglobin (Hb), hematocrit (HCT), number of platelets (PLT), and number of white blood cells (WBCs) were evaluated in different study groups. Also, the concentration of phosphate (P) and Body Mass Index (BMI) was estimated. In the end, the correlation test with each variable in different group studies was calculated by the STATISTICA program. The obtained results showed that there was a significant increase in the numbers of WBCs, the concentration of Cath-k, PTH, and BMI for the study groups compared to the control group, as well as a significant decrease in the concentration of P and Vit -D for the study groups compared to the control group. There is a significant increase in the E2 hormone in the group of pregnant women and a significant decrease in women with osteoporosis who are in menopause compared to the control group, as well as the presence of a significant decrease in RBCs, and Hb in the group of pregnant women compared to the control group. There is a significant increase in the numbers of PLT in the group of women with osteoporosis and women in menopause compared to the control group, as it is concluded from the current study that there is a close correlation between some different variables, including a good correlation between BMI and PLT was found to be 0.83. This may confirm that BMI is associated with increased cardiovascular morbidity and mortality through various molecular mechanisms possibly linking metabolic syndrome to hemostatic and vascular abnormalities in addition, a good correlation was observed between PTH and Cat-k (0.89), which indicated there is a relation between these two parameters.

Keywords

• Cat-k
• Vit-D
• Osteoporosis
• Correlation
• STATISTICA program
• Hematological variables
• Biochemical variables

References

1. [1] U. Windows, “Évaluation de la prise en charge de l’ostéoporose après fracture de hanche chez les patients de plus de 50 ans, dans le département du Lot-et-Garonne”.
2. [2] M. Birkhaeuser, “Healthy Bones After Menopause: What Has to Be Done?,” Int. Soc. Gynecol. Endocrinol. Ser., pp. 165–186, 2018, doi: 10.1007/978-3-319-63540-8_14/COVER.
3. [3] E. S. Siris et al., “Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures,” Arch. Intern. Med., vol. 164, no. 10, pp. 1108–1112, May 2004, doi: 10.1001/ARCHINTE.164.10.1108.
4. [4] S. A. Stoch and J. A. Wagner, “Cathepsin K Inhibitors: A Novel Target for Osteoporosis Therapy,” Clin. Pharmacol. Ther., vol. 83, no. 1, pp. 172–176, Jan. 2008, doi: 10.1038/SJ.CLPT.6100450.
5. [5] P. Garnero et al., “The collagenolytic activity of cathepsin K is unique among mammalian proteinases,” J. Biol. Chem., vol. 273, no. 48, pp. 32347–32352, Nov. 1999, doi: 10.1074/jbc.273.48.32347.
6. [6] B. D. Gelb, G. P. Shi, H. A. Chapman, and R. J. Desnick, “Pycnodysostosis, a Lysosomal Disease Caused by Cathepsin K Deficiency,” Science (80-. )., vol. 273, no. 5279, pp. 1236–1239, 1996, doi: 10.1126/SCIENCE.273.5279.1236.
7. [7] R. Kiviranta, J. Morko, H. Uusitalo, H. T. Aro, E. Vuorio, and J. Rantakokko, “Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K,” J. Bone Miner. Res., vol. 16, no. 8, pp. 1444–1452, 2001, doi: 10.1359/JBMR.2001.16.8.1444.
8. [8] K. Henriksen, L. B. Tanko, P. Qvist, P. D. Delmas, C. Christiansen, and M. A. Karsdal, “Assessment of osteoclast number and function: application in the development of new and improved treatment modalities for bone diseases”, doi: 10.1007/s00198-006-0286-8.

9. [9] G. Holzer, H. Noske, T. Lang, L. Holzer, and U. Willinger, “Soluble cathepsin K: A novel marker for the prediction of nontraumatic fractures?,” J. Lab. Clin. Med., vol. 146, no. 1, pp. 13–17, Jul. 2005, doi: 10.1016/J.LAB.2005.03.016.
10. [10] M. Muñoz-Torres et al., “Serum cathepsin K as a marker of bone metabolism in postmenopausal women treated with alendronate,” Maturitas, vol. 64, no. 3, pp. 188–192, Nov. 2009, doi: 10.1016/J.MATURITAS.2009.09.011.
11. [11] J. Pepe et al., “Higher serum levels of a cathepsin K-generated periostin fragment are associated with fractures in postmenopausal women with primary hyperparathyroidism: a pilot study”, doi: 10.1007/s00198-021-06018-x/Published.
12. [12] L. N. Nwosu et al., “Pain prediction by serum biomarkers of bone turnover in people with knee osteoarthritis: an observational study of TRAcP5b and cathepsin K in OA,” Osteoarthr. Cartil., vol. 25, no. 6, pp. 858–865, Jun. 2017, doi: 10.1016/J.JOCA.2017.01.002.
13. [13] G. Adami and K. G. Saag, “Glucocorticoid-induced osteoporosis: 2019 concise clinical review”, doi: 10.1007/s00198-019-04906-x.
14. [14] S. Rozenberg et al., “How to manage osteoporosis before the age of 50,” Maturitas, vol. 138, pp. 14–25, Aug. 2020, doi: 10.1016/J.MATURITAS.2020.05.004.
15. [15] M. Abbasian et al., “Vitamin D Deficiency in Pregnant Women and Their Neonates,” Glob. J. Health Sci., vol. 8, no. 9, 2016, doi: 10.5539/gjhs.v8n9p83.
16. [16] A. A. Ginde, A. F. Sullivan, J. M. Mansbach, and C. A. Camargo, “Vitamin D insufficiency in pregnant and nonpregnant women of childbearing age in the United States,” YMOB, vol. 202, pp. 436.e1-436.e8, 2010, doi: 10.1016/j.ajog.2009.11.036.
17. [17] L. A. J. L. M. Braam, A. P. G. Hoeks, F. Brouns, K. Halmuyák, M. J. W. Gerichhausen, and C. Vermeer, “Beneficial effects of vitamins D and K on the elastic properties of the vessel wall in postmenopausal women: A follow-up study,” Thromb. Haemost., vol. 91, no. 2, pp. 373–380, 2004, doi: 10.1160/TH03-07-0423/ID/JR0423-2/BIB.
18. [18] C. H. Cheng, L. R. Chen, and K. H. Chen, “Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover,” Int. J. Mol. Sci. 2022, Vol. 23, Page 1376, vol. 23, no. 3, p. 1376, Jan. 2022, doi: 10.3390/IJMS23031376.
19. [19] A. Calik-Ksepka, M. Stradczuk, K. Czarnecka, M. Grymowicz, and R. Smolarczyk, “Lactational Amenorrhea: Neuroendocrine Pathways Controlling Fertility and Bone Turnover,” Int. J. Mol. Sci. 2022, Vol. 23, Page 1633, vol. 23, no. 3, p. 1633, Jan. 2022, doi: 10.3390/IJMS23031633.
20. [20] S. Koka, T. M. Petro, and R. A. Reinhardt, “Estrogen Inhibits Interleukin-lβ-Induced Interleukin-6 Production by Human Osteoblast-like Cells,” https://home.liebertpub.com/jir, vol. 18, no. 7, pp. 479–483, Mar. 2009, doi: 10.1089/JIR.1998.18.479.
21. [21] J. M. Aitken, “Osteoporosis and its relation to estrogen deficiency,” Manag. Menopause Post-Menopausal Years, pp. 225–236, 1976, doi: 10.1007/978-94-011-6165-7_19.
22. [22] Z. Xu et al., “Mechanisms of estrogen deficiency-induced osteoporosis based on transcriptome and DNA methylation,” Front. Cell Dev. Biol., vol. 10, p. 1011725, Oct. 2022, doi: 10.3389/FCELL.2022.1011725/BIBTEX.
23. [23] F. F. Alyassin and M. Abbas Taher, “THE ROLE OF PROINFLAMMATORY CYTOKINES AND SOME HORMONES IN ENDOMETRIOSIS-INDUCED OSTEOPOROSIS,” Qar Med. J., vol. 9, no. 1, pp. 25–42, 2015.
24. [24] P. Pothiwala and S. N. Levine, “Parathyroid surgery in pregnancy: review of the literature and localization by aspiration for parathyroid hormone levels,” J. Perinatol., vol. 29, pp. 779–784, 2009, doi: 10.1038/jp.2009.84.
25. [25] J. Bover, J. Gunnarsson, P. Csomor, E. Kaiser, G. Cianciolo, and R. Lauppe, “Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis,” Clin. Kidney J., vol. 14, no. 10, pp. 2177–2186, Sep. 2021, doi: 10.1093/CKJ/SFAB035.
26. [26] D. Skolmowska, D. Głąbska, A. Kołota, and D. Guzek, “Effectiveness of Dietary Interventions to Treat Iron-Deficiency Anemia in Women: A Systematic Review of Randomized Controlled Trials,” Nutrients, vol. 14, no. 13, p. 2724, Jul. 2022, doi: 10.3390/NU14132724/S1.
27. [27] E. D. M. Gallery, S. N. Hunyor, and A. Z. Györy, “Plasma Volume Contraction: A Significant Factor in Both Pregnancy-Associated Hypertension (Pre Eclampsia) and Chronic Hypertension in Pregnancy,” QJM An Int. J. Med., vol. 48, no. 4, pp. 593–602, Oct. 1979, doi: 10.1093/OXFORDJOURNALS.QJMED.A067595.
28. [28] J. Che et al., “The Effect of Abnormal Iron Metabolism on Osteoporosis”, doi: 10.1007/s12011-019-01867-4.
29. [29] I. Kale, “Journal of Clinical and Investigative Surgery The predictive role of monocyte-lymphocyte ratio and platelet-lymphocyte ratio in postmenopausal osteoporosis,” J Clin Invest Surg, vol. 6, no. 2, pp. 141–147, 2021, doi: 10.25083/2559-5555.
30. [30] S. Chandra, A. K. Tripathi, S. Mishra, M. Amzarul, and A. K. Vaish, “Physiological changes in hematological parameters during pregnancy,” Indian J. Hematol. Blood Transfus., vol. 28, no. 3, pp. 144–146, Sep. 2012, doi: 10.1007/S12288-012-0175-6/METRICS.
31. [31] H. Safari, M. Hajian, M. Hossein Nasr-Esfahani, M. Forouzanfar, and J. R. Drevet, “Vitamin D and calcium, together and separately, play roles in female reproductive performance,” Sci. Reports |, vol. 12, p. 10470, 123AD, doi: 10.1038/s41598-022-14708-7.
32. [32] D. Goltzman, “Functions of vitamin D in bone,” Histochem. Cell Biol., vol. 149, no. 4, pp. 305–312, Apr. 2018, doi: 10.1007/S00418-018-1648-Y/FIGURES/4.
33. [33] E. Koumakis, C. Cormier, C. Roux, and K. Briot, “The Causes of Hypo- and Hyperphosphatemia in Humans,” vol. 108, pp. 41–73, 2021, doi: 10.1007/s00223-020-00664-9.
34. [34] G. Lee, S. Choi, Y. Cho, and S. M. Park, “Risk of Osteoporotic Fractures Among Obese Women Based on Body Mass Index and Waist Circumference: A Nationwide Cohort in South Korea,” Clin. Nutr. Res., vol. 11, no. 1, p. 32, 2022, doi: 10.7762/CNR.2022.11.1.32.
35. [35] S. Gnudi, E. Sitta, and L. Lisi, “Relationship of body mass index with main limb fragility fractures in postmenopausal women,” J. Bone Miner. Metab., vol. 27, no. 4, pp. 479–484, Jul. 2009, doi: 10.1007/S00774-009-0056-8/TABLES/4.
36. [36] M. W. Hamrick and S. L. Ferrari, “Leptin and the sympathetic connection of fat to bone”, doi: 10.1007/s00198-007-0487-9.
37. [37] M. W. Hamrick and S. L. Ferrari, “Leptin and the sympathetic connection of fat to bone,” Osteoporos. Int., vol. 19, no. 7, pp. 905–912, Jul. 2008, doi: 10.1007/S00198-007-0487-9/FIGURES/1.
38. [38] G. Aparecido Foratori-Junior, P. Ramos Pereira, I. Antunes Gasparoto, S. Helena de Carvalho Sales-Peres, J. Moura Storniolo de Souza, and S. Khan, “Is overweight associated with periodontitis in pregnant women? Systematic review and meta-analysis ☆”, doi: 10.1016/j.jdsr.2022.01.001.
39. [39] K. Gkastaris, D. G. Goulis, M. Potoupnis, A. D. Anastasilakis, and G. Kapetanos, “Obesity, osteoporosis and bone metabolism”.
40. [40] S. Lotinun et al., “Cathepsin K–deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression,” J. Clin. Invest., vol. 129, no. 8, pp. 3058–3071, Aug. 2019, doi: 10.1172/JCI122936.
41. [41] D. Bolignano et al., “Increased circulating Cathepsin-K levels reflect PTH control in chronic hemodialysis patients,” vol. 34, pp. 451–458, 2021, doi: 10.1007/s40620-020-00801-5.